Retatrutide

Retatrutide is currently in Phase 3 clinical trials through Eli Lilly's TRIUMPH program. The first Phase 3 readout (TRIUMPH-4) came in December 2025 showing 28.7% weight loss. Seven additional readouts are expected throughout 2026. Most analysts project an FDA submission in late 2026, with potential approval in the first half of 2027 and market availability by mid-to-late 2027. These timelines could shift based on remaining trial results and regulatory review.

In cross-trial comparisons, retatrutide produced substantially more weight loss: 28.7% at 68 weeks (Phase 3) versus tirzepatide's 20.9% at 72 weeks and semaglutide's 14.9% at 68 weeks. Retatrutide also showed dramatically better liver fat reduction at 86% versus 37-53% for tirzepatide. However, retatrutide is not yet approved, has higher GI side effect rates, and introduced a new safety signal called dysesthesia not seen with the other two agents. Head-to-head trials have not been conducted.

Tirzepatide activates two receptors (GIP and GLP-1), while retatrutide adds a third: the glucagon receptor. Glucagon activation increases energy expenditure through thermogenesis and promotes direct fat oxidation, particularly in the liver. This creates both an "eat less" and "burn more" effect simultaneously in a single molecule. The glucagon component likely explains retatrutide's superior liver fat clearance and faster weight loss trajectory compared to tirzepatide.

No. Retatrutide is only available through enrollment in Eli Lilly's Phase 3 TRIUMPH clinical trials. It is not available by prescription, from compounding pharmacies, or from research peptide vendors. The FDA has explicitly stated retatrutide cannot be legally compounded under federal law. Any product marketed as retatrutide outside of clinical trials is unregulated, unverified, and potentially dangerous.

The most common side effects are gastrointestinal: nausea (38-43%), diarrhea (33-35%), constipation (22-25%), and vomiting (20-21%). These are dose-dependent and typically improve with gradual titration over 8-12 weeks. Phase 3 revealed a new safety signal called dysesthesia — abnormal touch sensations occurring in 8.8% at the 9 mg dose and 20.9% at 12 mg. Modest heart rate increases of 5-10 bpm are consistent with the GLP-1 medication class.

Phase 2a data published in Nature Medicine (PMID: 38858523) showed dramatic liver fat reduction: 86% relative reduction at 48 weeks, with 86% of participants at the highest dose achieving normal liver fat levels below the 5% threshold at 24 weeks. This significantly outperforms both semaglutide and tirzepatide for liver fat reduction. The TRIUMPH Phase 3 program includes dedicated MASH/MASLD endpoints. If confirmed, fatty liver disease could become a major secondary indication for retatrutide.

Phase 2 data showed 24.2% body weight loss at 48 weeks at the 12 mg dose. Phase 3 TRIUMPH-4 results extended this to 28.7% at 68 weeks — approximately 71.2 pounds on average. At the highest dose, 100% of Phase 2 participants lost at least 5% of body weight and 83% lost at least 15%. These represent the highest weight loss results reported for any pharmaceutical agent in clinical trials to date.

Yes, some lean mass loss occurs with retatrutide, as with all medications that produce significant weight loss. The Phase 2 body composition substudy (PMID: 40609566) documented up to 6.5 kg of lean mass loss. However, the ratio of lean to total weight loss was comparable to other obesity treatments including semaglutide. Researchers recommend resistance training two to three times per week and protein intake of 1.2 to 1.6 grams per kilogram daily to help preserve muscle during treatment.

Phase 2 trials used a titration schedule starting at 1 mg weekly, increasing every 4 weeks through 2 mg, 4 mg, 8 mg, to a maximum of 12 mg. Phase 3 TRIUMPH trials are testing 9 mg and 12 mg maintenance doses along with a 4 mg maintenance arm for patients who respond well at lower doses. Gradual titration is critical for tolerability — GI side effect rates nearly doubled when dose escalation was too rapid. All dosing information reflects clinical trial protocols since retatrutide is not yet FDA-approved.

No official pricing has been announced since retatrutide is not yet approved. Based on Eli Lilly's pricing for tirzepatide (Zepbound at approximately $1,060 per month), analysts project retatrutide would be priced similarly or higher as a premium next-generation treatment — likely in the range of $1,100 to $1,400 per month. Insurance coverage policies will depend on the specific FDA-approved indications and will take time to develop after launch.

Not necessarily. While retatrutide produces greater average weight loss, individual patients respond differently to medications. Some may tolerate semaglutide or tirzepatide better, particularly given retatrutide's higher GI side effect rates and the new dysesthesia safety signal. Cost, insurance coverage, and individual tolerability will determine which medication is best for each person. Having multiple effective options benefits patients overall.

Dysesthesia is an abnormal sensation of touch where normal stimuli feel unusual, tingling, or mildly painful. It was identified as a new safety signal in the Phase 3 TRIUMPH-4 trial, occurring in 8.8% of participants at the 9 mg dose and 20.9% at 12 mg versus just 0.7% on placebo. This was not observed in earlier Phase 2 trials. Reports indicate it was generally mild and infrequently led to treatment discontinuation. Researchers and regulatory agencies are monitoring this finding closely in subsequent TRIUMPH readouts.

The TRIUMPH-4 Phase 3 trial specifically studied retatrutide in adults with obesity and knee osteoarthritis. Results showed a 75.8% reduction in WOMAC knee pain scores, with approximately one in eight participants becoming completely free of knee pain at the end of the 68-week trial. The benefits likely come from substantial weight loss reducing mechanical joint stress, though direct anti-inflammatory effects of the medication have not been ruled out.

Search ClinicalTrials.gov for "retatrutide" to find active TRIUMPH studies. Multiple trials are currently listed in the United States. Eligibility typically requires a BMI of 30 or higher, or 27 or higher with weight-related comorbidities such as diabetes, sleep apnea, or osteoarthritis. Trial sites are located across the country and enrollment availability varies by location and study phase.

TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide, using a novel basket trial design that tests the compound simultaneously for multiple conditions. The program includes TRIUMPH-1 and TRIUMPH-2 (weight management with nested obstructive sleep apnea and osteoarthritis protocols), TRIUMPH-3 (weight management in people with cardiovascular disease over 113 weeks), and TRIUMPH-4 (knee osteoarthritis, first readout completed December 2025). Over 5,800 participants are enrolled across all studies.

Retatrutide is being tested for obstructive sleep apnea within the TRIUMPH basket trials using the apnea-hypopnea index (AHI) as an endpoint. No sleep apnea-specific results have been published yet. Given that retatrutide produces approximately 28% body weight loss and weight loss is the primary treatment for obesity-related sleep apnea, clinically meaningful improvements in AHI scores are anticipated. Semaglutide has already demonstrated AHI improvement in its own dedicated trial.

Phase 2 data (PMID: 37385280) in patients with type 2 diabetes showed robust glycemic control with HbA1c reduction of up to 2.02% alongside significant weight loss, outperforming both placebo and dulaglutide. The safety profile was consistent with other GLP-1 agonists. However, retatrutide's glucagon receptor component adds complexity to blood glucose management since glucagon raises blood glucose while GLP-1 and GIP lower it. The TRIUMPH program includes dedicated trials for the diabetes population.

No dedicated retatrutide discontinuation studies exist yet. Based on data from similar GLP-1 medications, weight regain after stopping is a documented concern: semaglutide users regained approximately two-thirds of lost weight within one year of stopping in published studies, and tirzepatide users regained about 14% of body weight after switching to placebo. Maintaining weight loss likely requires continued lifestyle modifications including structured nutrition, regular exercise, and potentially long-term pharmacotherapy.